Trial Profile
A multinational, open-label, non-controlled trial on safety, efficacy and pharmacokinetics of NNC 0129-0000-1003 in previously treated paediatric patients with severe haemophilia A
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jan 2022
Price :
$35
*
At a glance
- Drugs Turoctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Acronyms PATHFINDER 5
- Sponsors Novo Nordisk
- 01 Jan 2022 Results of post-hoc analysis of two studies (pathfinder 2 and pathfinder 5) assessing long-term efficacy and pharmacokinetic outcomes with fixed-dose N8-GP prophylaxis, published in the Haemophilia.
- 01 Sep 2020 End-of-trial safety and efficacy results of the combined main and extension phases published in the Journal of Thrombosis and Haemostasis
- 09 Mar 2020 Results of NCT01731600 and NCT01480180 assesing plasma polyethylene glycol concentrations, repeatedly treated with N8-GP for periods of up to 5 years, published in the Drugs in R and D.